Market Overview

UPDATE: Wedbush Raises PT to $5 on Xoma on Gevokizumab Initial Efficacy

Related XOMA
XOMA Initiates U.S. Clinical Trial of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD - US
MLV & Co Has Positive Outlook On XOMA

Wedbush reiterated its Outperform rating on Xoma (NASDAQ: XOMA) and raised its price target from $4 to $5.

Wedbush commented, "Xoma announced that Gevokizumab demonstrated initial clinical efficacy as a treatment candidate for severe inflammatory acne. Interim results from 92 of 125 enrolled patients to date showed that the higher of two doses (0.2 and 0.6 mg/kg) of Gevokizumab demonstrated a consistent mean reduction from an average baseline of 31 inflammatory lesions to 19 through Day 84 with statistically significant reduction on Day 42 (p=0.077 based on 80% power to achieve p<0.10)."

Xoma closed at $2.77 on Friday.

Latest Ratings for XOMA

DateFirmActionFromTo
Apr 2014McNicoll Lewis VlakUpgradesHoldBuy
Mar 2014McNicoll Lewis ValkDowngradesBuyHold
Mar 2014Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for XOMA
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (XOMA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters